The challenge
GangaGen Life Sciences Inc., a developer of bacteriophage technology used in the prevention of food-borne disease, needed to bring its capabilities to the attention of general business and trade media.
What inmedia did
We conducted a classic media launch of GangaGen and its technology. Targeting mainly Canadian media, we focused on GangaGen’s first application that would address E. coli O157:H7, a sometimes fatal bacterial infection transmitted to humans through beef products.
The result
This early first step produced good coverage for GangaGen in some of its key target media – business, general media and life sciences and biotechnology publications.
What our client said
“Because the impetus behind our technology is to protect the public from harmful bacteria, ours is a worthwhile news story to the general public. inmedia has increased awareness not only within the life sciences, biotechnology and business realms, but also with the people that we are working hard to protect.”
– Rainer Engelhardt, CEO, GangaGen Life Sciences Inc.
